Wedbush analyst Liana Moussatos reiterated a Buy rating on United Therapeutics (NASDAQ:UTHR) on Monday, setting a price target of $276, which is approximately 35.47% above the present share price of $203.73.
Moussatos expects United Therapeutics to post earnings per share (EPS) of $2.22 for the second quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in United Therapeutics, with an average price target of $228.25.
The analysts price targets range from a high of $276 to a low of $195.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $384.9 million and a net profit of $65.3 million. The company's market cap is $9.08 billion.
According to TipRanks.com, Wedbush analyst Liana Moussatos is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 10.5% and a 46.34% success rate.
United Therapeutics Corp . operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.